MA38679B1 - Modulateurs du récepteur de cxcr7 - Google Patents

Modulateurs du récepteur de cxcr7

Info

Publication number
MA38679B1
MA38679B1 MA38679A MA38679A MA38679B1 MA 38679 B1 MA38679 B1 MA 38679B1 MA 38679 A MA38679 A MA 38679A MA 38679 A MA38679 A MA 38679A MA 38679 B1 MA38679 B1 MA 38679B1
Authority
MA
Morocco
Prior art keywords
cxcr7
modulators
receiver modulators
formula
receiver
Prior art date
Application number
MA38679A
Other languages
English (en)
Other versions
MA38679A1 (fr
Inventor
Thierry Kimmerlin
Heinz Fretz
Philippe Guerry
Francois Lehembre
Julien Pothier
Hervé Siendt
Anja Valdenaire
Original Assignee
Idorsia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idorsia Pharmaceuticals Ltd filed Critical Idorsia Pharmaceuticals Ltd
Publication of MA38679A1 publication Critical patent/MA38679A1/fr
Publication of MA38679B1 publication Critical patent/MA38679B1/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/04Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56Nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/06Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Liquid Crystal Substances (AREA)

Abstract

L'invention concerne des dérivés de formule (i), dans laquelle (r1)n, r 2a, r 2b, r 3a, r 3b, r 4, l1, l2, x, y et ar1 sont tels que définis dans la description, ainsi que leur préparation, des sels pharmaceutiquement acceptables de ceux-ci et leur utilisation en tant que produits pharmaceutiques, des compositions pharmaceutiques contenant au moins un composé de formule (i), et en particulier leur utilisation en tant que modulateurs du récepteur de cxcr7
MA38679A 2013-05-30 2014-05-28 Modulateurs du récepteur de cxcr7 MA38679B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IB2013054478 2013-05-30
PCT/IB2014/061774 WO2014191929A1 (fr) 2013-05-30 2014-05-28 Modulateurs du récepteur de cxcr7

Publications (2)

Publication Number Publication Date
MA38679A1 MA38679A1 (fr) 2018-07-31
MA38679B1 true MA38679B1 (fr) 2019-12-31

Family

ID=50943357

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38679A MA38679B1 (fr) 2013-05-30 2014-05-28 Modulateurs du récepteur de cxcr7

Country Status (30)

Country Link
US (1) US9920010B2 (fr)
EP (1) EP3004082B1 (fr)
JP (1) JP6393749B2 (fr)
KR (1) KR102302580B1 (fr)
CN (1) CN105263924B (fr)
AR (1) AR096490A1 (fr)
AU (1) AU2014272718B2 (fr)
BR (1) BR112015030095B1 (fr)
CA (1) CA2912133C (fr)
CL (1) CL2015003470A1 (fr)
CY (1) CY1119537T1 (fr)
DK (1) DK3004082T3 (fr)
EA (1) EA028604B1 (fr)
ES (1) ES2645470T3 (fr)
HR (1) HRP20171597T1 (fr)
HU (1) HUE036649T2 (fr)
IL (1) IL242782B (fr)
LT (1) LT3004082T (fr)
MA (1) MA38679B1 (fr)
MX (1) MX364104B (fr)
MY (1) MY173564A (fr)
NO (1) NO3004082T3 (fr)
PH (1) PH12015502632B1 (fr)
PL (1) PL3004082T3 (fr)
PT (1) PT3004082T (fr)
SG (1) SG11201509057UA (fr)
SI (1) SI3004082T1 (fr)
TW (1) TWI640510B (fr)
UA (1) UA118562C2 (fr)
WO (1) WO2014191929A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR091516A1 (es) 2012-06-22 2015-02-11 Actelion Pharmaceuticals Ltd Derivados de 1-[m-carboxamido(hetero)aril-metil]-heterociclil-carboxamida
WO2016087370A1 (fr) 2014-12-01 2016-06-09 Actelion Pharmaceuticals Ltd Modulateurs du récepteur cxcr7
WO2017070431A1 (fr) * 2015-10-23 2017-04-27 James Merritt Utilisation d'antagonistes de ccr1 en tant que traitement de tumeurs du système nerveux central
KR102497095B1 (ko) * 2016-07-28 2023-02-06 이도르시아 파마슈티컬스 리미티드 피페리딘 cxcr7 수용체 조절제
AR111941A1 (es) 2017-05-18 2019-09-04 Idorsia Pharmaceuticals Ltd Derivados de pirimidina como moduladores del receptor de pge2
MX388257B (es) 2017-05-18 2025-03-19 Idorsia Pharmaceuticals Ltd Derivados de pirimidina como moduladores del receptor de pge2.
TWI822724B (zh) 2018-01-26 2023-11-21 瑞士商愛杜西亞製藥有限公司 唑-3-羰基]-胺基}-哌啶-3-羧酸(1-嘧啶-2-基-環丙基)-醯胺之結晶型

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3896170A (en) 1969-02-26 1975-07-22 American Home Prod Intermediates for the preparation of 1,3-dihydro-2h-1, -benzodiazepin-2-ones
HUP0101280A3 (en) 1998-02-18 2003-02-28 Neurosearch As Positive ampa receptor modulator compounds and their use
GB9816984D0 (en) * 1998-08-05 1998-09-30 Smithkline Beecham Plc Novel compounds
JP2004515494A (ja) 2000-12-07 2004-05-27 アストラゼネカ・アクチエボラーグ 治療剤
CN1747929B (zh) * 2002-12-20 2010-04-28 坎莫森特里克斯公司 趋化因子i-tac或sdf-1结合于ccxckr2受体的抑制剂
WO2007059108A2 (fr) * 2005-11-10 2007-05-24 Chemocentryx, Inc. Quinolones substituees et procedes d'utilisation
WO2009076404A1 (fr) 2007-12-10 2009-06-18 Epix Delaware, Inc. Composés de carboxyamide et leur utilisation comme antagonistes du récepteur ccr2de la chimiokine
AR091516A1 (es) * 2012-06-22 2015-02-11 Actelion Pharmaceuticals Ltd Derivados de 1-[m-carboxamido(hetero)aril-metil]-heterociclil-carboxamida
WO2016087370A1 (fr) 2014-12-01 2016-06-09 Actelion Pharmaceuticals Ltd Modulateurs du récepteur cxcr7

Also Published As

Publication number Publication date
UA118562C2 (uk) 2019-02-11
CN105263924A (zh) 2016-01-20
MA38679A1 (fr) 2018-07-31
HUE036649T2 (hu) 2018-07-30
AU2014272718A1 (en) 2016-01-21
SG11201509057UA (en) 2015-12-30
PH12015502632A1 (en) 2016-03-07
KR20160013197A (ko) 2016-02-03
EA028604B1 (ru) 2017-12-29
BR112015030095B1 (pt) 2023-02-28
AU2014272718B2 (en) 2018-06-28
KR102302580B1 (ko) 2021-09-15
JP6393749B2 (ja) 2018-09-19
MX364104B (es) 2019-04-12
SI3004082T1 (sl) 2017-11-30
US9920010B2 (en) 2018-03-20
CY1119537T1 (el) 2018-03-07
LT3004082T (lt) 2017-10-25
CN105263924B (zh) 2018-10-19
IL242782B (en) 2019-06-30
WO2014191929A1 (fr) 2014-12-04
HRP20171597T1 (hr) 2017-12-01
HK1223353A1 (en) 2017-07-28
NZ715530A (en) 2020-12-18
MX2015016429A (es) 2016-03-01
MY173564A (en) 2020-02-04
US20160107997A1 (en) 2016-04-21
CA2912133C (fr) 2021-06-22
EP3004082B1 (fr) 2017-08-02
ES2645470T3 (es) 2017-12-05
CL2015003470A1 (es) 2016-06-17
PT3004082T (pt) 2017-11-13
TW201529557A (zh) 2015-08-01
EP3004082A1 (fr) 2016-04-13
PL3004082T3 (pl) 2018-01-31
DK3004082T3 (en) 2017-10-02
PH12015502632B1 (en) 2016-03-07
TWI640510B (zh) 2018-11-11
CA2912133A1 (fr) 2014-12-04
BR112015030095A2 (pt) 2022-07-12
JP2016520120A (ja) 2016-07-11
EA201501163A1 (ru) 2016-06-30
AR096490A1 (es) 2016-01-13
NO3004082T3 (fr) 2017-12-30
IL242782A0 (en) 2016-02-01

Similar Documents

Publication Publication Date Title
MA45782B1 (fr) Modulateurs du récepteur de cxcr7 pipéridine
MA37400B1 (fr) Composés hétérocyclyle en tant qu'inhibiteurs de mek
MA38679B1 (fr) Modulateurs du récepteur de cxcr7
MA42230B1 (fr) Dérivés bicycliques, leur procédé de préparation, et compositions pharmaceutiques les contenant
MA42678B1 (fr) Nouveaux analogues nucléosidiques substitués à cycle aromatique bicyclique 6-6 pour une utilisation en tant qu'inhibiteurs de prmt5
MA40111B1 (fr) Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1
MA42231B1 (fr) Nouveaux dérivés d'hydroxyacide, leur procédé de préparation, et compositions pharmaceutiques les contenant
MA35749B1 (fr) Dérivés nucléosidiques 4'-azido, 3'-fluoro substitués en tant qu'inhibiteurs de la réplication de l'arn du vhc
MX375978B (es) Derivados de indol n-sustituidos como moduladores de los receptores de pge2.
MA34083B1 (fr) Compositions pharmaceutques de composé spiro-oxindole pour administration topique et leur utilisation en tant qu'agents thérapeutiques
UA109220C2 (uk) Похідні (4-фенілімідазол-2-іл)етиламіну як модулятори натрієвих каналів
MY169986A (en) Benzimidazole-proline derivatives
MA49127B1 (fr) Dérivés d'indole n-substitués
MA38854B1 (fr) Dérivés amides utilisés en tant qu'antagonistes des récepteurs de l'acide lysophosphatidique
MA35893B1 (fr) Dérivés d'amide hétérocyclique comme antagonistes du récepteur p2x7
MA39165A1 (fr) Dérivés de benzimidazole-proline pour leurs utilisations dans le traitement du syndrome des etats crepusculaires
MA40366A (fr) Dérivés de tétrahydroquinoline à titre d'inhibiteurs des bromodomaines
UA103329C2 (ru) Соли соединений-ингибиторов вич
MA38410A1 (fr) Composés d'azétidinyloxyphénylpyrrolidine
MA44965A (fr) Dérivés de pyridinyle, compositions pharmaceutiques et utilisations de ceux-ci en tant qu'inhibiteurs d'aoc3
MA39229A1 (fr) Pyrrolidines, térahydrofuranes et cyclopentanes substitués utiles en tant qu'antagonistes des récepteurs des orexines
MA35010B1 (fr) Inhibiteurs de la peptide déformylase
IN2014MN02433A (fr)
MA37879B1 (fr) Forme amorphe stabilisée d'agomélatine, procédé pour sa préparation et compositions pharmaceutiques la contenant
MX2015012575A (es) Novedosos derivados de acrilamida como agentes contra la malaria.